| Somaini, Silvia Ulrich |
HEXA, NCT04697875: Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%) | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXASH, NCT04697862: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%) under Sildenafil, Normobaric hypoxia (FiO2 15%) | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXASN, NCT04706546: Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil |
|
|
| Completed | N/A | 24 | Europe | Hemodynamic effect of exercise under Sildenafil, Hemodynamic effect of exercise | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
NCT02558582: Effect of Exercise Training in Patients With Pulmonary Hypertension |
|
|
| Recruiting | N/A | 32 | Europe | respiratory and exercise therapy, respiratory and exercise therapy with supplemental oxygen | University of Zurich | Hypertension, Pulmonary | 12/23 | 12/23 | | |
NCT06480656: Eccentric Cycling Exercise During Pulmonary Rehabilitation Pulmonary Vascular Disease |
|
|
| Recruiting | N/A | 22 | Europe | Rehabilitation with eccentric cycling exercise, normal rehabilitation | University of Zurich | Eccentric Cycling Exercise | 06/26 | 07/26 | | |
| Ulrich, Silvia |
NCT03539367: Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude |
|
|
| Active, not recruiting | 4 | 100 | RoW | ACETAZOLAMIDE oral capsule, Placebo oral capsule | University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | Altitude Hypoxia | 12/22 | 12/22 | | |
NCT03537924: Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude |
|
|
| Active, not recruiting | 4 | 100 | RoW | ACETAZOLAMIDE oral capsule, Placebo oral capsule | University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | Altitude Hypoxia | 12/22 | 12/22 | | |
NCT06498505: HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men |
|
|
| Recruiting | 4 | 270 | RoW | Acetazolamide, Placebo | University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov, University Hospital Heidelberg, Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques | High Altitude | 12/25 | 12/25 | | |
NCT03540914: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. |
|
|
| Active, not recruiting | 4 | 400 | RoW | ACETAZOLAMIDE oral capsule, Placebo oral capsule | University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | Altitude Hypoxia | 12/24 | 12/24 | | |
NCT04915365: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude |
|
|
| Recruiting | 3 | 100 | RoW | Acetazolamide, Acetazolamide, oral capsule, Placebo, Placebo, oral capsule | University of Zurich, National Center of Cardiology and Internal Medicine, Kyrgyz Republic | Right Heart Function, Chronic Obstructive Pulmonary Disease, Altitude Sickness | 12/22 | 12/23 | | |
ESRA, NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH |
|
|
| Recruiting | 2 | 70 | Europe | Riociguat Oral Tablet, MK-4836, ATC Code: C02KX05, Placebo | Heidelberg University, Merck Sharp & Dohme LLC | Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue | 10/25 | 06/26 | | |
PEGASUS, NCT03051763: The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension |
|
|
| Recruiting | N/A | 1000 | Europe | | University of Giessen, Universitätsklinikum Hamburg-Eppendorf, DRK Kliniken Berlin Köpenick, Berlin, Germany, University Hospital, Zürich, University Hospital Carl Gustav Carus | Pulmonary Hypertension, Pulmonary Arterial Hypertension | 12/21 | 05/22 | | |
NCT05185895: Visa-versa! Breaking Instead of Pushing the Pedals-D |
|
|
| Completed | N/A | 24 | Europe | 15 minutes eccentric cycling, 15 minutes concentric (normal) cycling | University of Zurich | Healthy (Controls) | 12/22 | 04/23 | | |
NCT05186987: Visa-versa! Breaking Instead of Pushing the Pedals-A |
|
|
| Completed | N/A | 33 | Europe | 15 minutes eccentric cycling, 15 minutes concentric (normal) cycling | University of Zurich | Pulmonary Hypertension | 08/23 | 09/23 | | |
HEXAS, NCT04704440: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXASN, NCT04706546: Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil |
|
|
| Completed | N/A | 24 | Europe | Hemodynamic effect of exercise under Sildenafil, Hemodynamic effect of exercise | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXABM, NCT04715113: Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXA, NCT04697875: Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%) | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
HEXASH, NCT04697862: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil |
|
|
| Completed | N/A | 24 | Europe | Normobaric hypoxia (FiO2 15%) under Sildenafil, Normobaric hypoxia (FiO2 15%) | University of Zurich | Hypertension, Pulmonary | 05/23 | 05/23 | | |
| Recruiting | N/A | 1500 | Europe, US, RoW | assessment of pulmonary hemodynamics during exercise by right heart catheterization | Medical University of Graz, European Respiratory Society | Pulmonary Circulation Diseases | 12/29 | 12/29 | | |
NCT05185856: Visa-versa! Breaking Instead of Pushing the Pedals-B |
|
|
| Recruiting | N/A | 16 | Europe | 15 minutes eccentric cycling, 15 minutes concentric (normal) cycling | University of Zurich | Chronic Obstructive Pulmonary Disease | 07/24 | 12/24 | | |
NCT05204693: Visa-versa! Breaking Instead of Pushing the Pedals-C |
|
|
| Recruiting | N/A | 16 | Europe | 15 minutes eccentric cycling, 15 minutes concentric (normal) cycling | University of Zurich | Left Heart Failure | 12/23 | 07/24 | | |
NCT05996302: HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level) |
|
|
| Active, not recruiting | N/A | 24 | Europe | Relocation to sea level | University of Zurich | Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 12/23 | 12/23 | | |
NCT06084559: HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT) |
|
|
| Active, not recruiting | N/A | 24 | Europe | Supplemental oxygen therapy, Sham Oxygen therapy, Placebo | University of Zurich | Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 12/23 | 12/23 | | |
NCT06072417: HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level) |
|
|
| Active, not recruiting | N/A | 24 | Europe | Assessment without intervention at High altitude, Relocation to sea level for 2 days | University of Zurich | Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 12/23 | 12/23 | | |
NCT06003244: High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT) |
|
|
| Active, not recruiting | N/A | 24 | Europe | 6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal) | University of Zurich | Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 12/23 | 12/23 | | |
NCT06385301: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases |
|
|
| Not yet recruiting | N/A | 14 | Europe | 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal) | University of Zurich | Lung Disease Chronic, Lung Diseases, Interstitial, Lung Diseases, Obstructive | 05/25 | 11/25 | | |
NCT06384534: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) |
|
|
| Not yet recruiting | N/A | 28 | Europe | 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen | University of Zurich | Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension | 05/25 | 11/25 | | |
NCT06489691: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m) |
|
|
| Not yet recruiting | N/A | 24 | RoW | 6-minute walk test (6MWT) | University of Zurich | High Altitude Pulmonary Hypertension | 12/24 | 12/24 | | |
NCT06489717: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m) |
|
|
| Not yet recruiting | N/A | 24 | RoW | SDB assessment | University of Zurich | High Altitude Pulmonary Hypertension | 12/24 | 12/24 | | |
NCT06489704: High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m) |
|
|
| Not yet recruiting | N/A | 24 | RoW | Echocardiography | University of Zurich | High Altitude Pulmonary Hypertension | 12/24 | 12/24 | | |
NCT06489756: Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) |
|
|
| Not yet recruiting | N/A | 24 | RoW | Echocardiography | University of Zurich | High Altitude Pulmonary Hypertension | 12/24 | 12/24 | | |
NCT06489743: Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) |
|
|
| Not yet recruiting | N/A | 24 | RoW | 6-minute walk test (6MWT) | University of Zurich | High Altitude Pulmonary Hypertension | 12/24 | 12/24 | | |
NCT06489730: HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders. |
|
|
| Not yet recruiting | N/A | 120 | NA | | University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | High Altitude Pulmonary Hypertension, Sleep Apnea | 12/24 | 12/24 | | |
| Recruiting | N/A | 100 | Europe | PH target therapy according to physician | University of Zurich | Pulmonary Hypertension Outcome Assessment | 09/24 | 09/24 | | |
| Recruiting | N/A | 1000 | Europe | | University of Zurich, Actelion | Pulmonary Hypertension | 12/27 | 12/27 | | |
